Location History:
- Hirschberg a.d.B, DE (2019)
- Hirschberg a.d.B., DE (2021)
Company Filing History:
1 out of 155 
1 out of 63 
1 out of 14 
Years Active: 2019-2021
Title: Clemens Kratochwil: Innovator in Radiopharmaceuticals
Introduction
Clemens Kratochwil is a notable inventor based in Munich, Germany. He has made significant contributions to the field of radiopharmaceuticals, particularly in the treatment of prostate cancer. With a total of 2 patents, his work has the potential to impact cancer treatment methodologies.
Latest Patents
Kratochwil's latest patents include innovative methods for treating PSMA expressing cancers. The first patent describes a method that involves administering Ac-225-radiopharmaceuticals to patients in need, with specific dosage guidelines ranging from 25 kBq to 400 kBq/kg of body weight. The second patent focuses on labeled inhibitors of prostate-specific membrane antigen (PSMA), which serve as imaging agents and pharmaceutical agents for treating prostate cancer. This invention highlights the use of radiopharmaceuticals in nuclear medicine, emphasizing their role as tracers and imaging agents.
Career Highlights
Throughout his career, Kratochwil has worked with esteemed institutions such as the German Cancer Research Center and Heidelberg University. His research has been pivotal in advancing the understanding and treatment of prostate cancer through innovative radiopharmaceutical applications.
Collaborations
Some of his notable coworkers include Uwe Haberkorn and Matthias Eder, who have collaborated with him on various projects in the field of nuclear medicine and cancer research.
Conclusion
Clemens Kratochwil's contributions to the field of radiopharmaceuticals demonstrate his commitment to improving cancer treatment options. His innovative patents and collaborations with leading institutions highlight his role as a key figure in medical research.